Session Abstract

Session Synopsis: Emerging NGS technologies promise to revolutionize applications in the clinic. They are continuously becoming more affordable, yet the requirements for high accuracy, speed, and better reliability remain. This panel will focus on the newest advancements and the technical challenges they encounter to advancing genomics into the clinic, as well as the requirements needed to optimize patient care.

Session Chair Profile

International Business Leader, Roche Molecular Systems, Inc.
Biography

Allison Ballmer is an International Business Leader at Roche Sequencing, focused on advancing Next Generation Sequencing platforms into the clinic. Prior to joining Roche, Ballmer led Global Marketing and Commercialization for Swiss-based Molecular Diagnostics arm of Biocartis. She held various Business Development and Commercial leadership roles in Molecular Diagnostics with a particular emphasis in Oncology. She began her career in Cancer Diagnostics holding leadership roles in Quality, Regulatory and Operations Management. Ms Ballmer serves on the Advisory Board of Techbridge Girls, a non-profit advancing girls and underrepresented minorities in STEM. She earned her B.S. in Mechanical Engineering from Virginia Tech and Marketing certifications from Cornell University. She is a certified practitioner of Internal Family Systems Therapy and enjoys mentoring and coaching in her free time.

Speaker Profile

Ph.D., Co-Founder and Chief Executive Officer, 10x Genomics
Biography

Serge Saxonov co-founded 10x Genomics in 2012 and has served as the CEO since its inception. Prior to 10x Genomics, Serge was VP of Applications at QuantaLife, where he was responsible for building content, driving new applications, and identifying key diagnostics opportunities for the core ddPCR technology. Before QuantaLife, Serge was Founding Architect and Director of R&D at 23andMe. There he defined the initial conception of the product, built many elements of the technology, and drove strategy and execution of R&D functions as the company scaled. Serge received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics and biology from Harvard University.

Speaker Profile

CEO, Genia
Biography

Stefan Roever has a broad entrepreneurial, software, and finance background. He is the CEO of Genia Technologies, a next generation DNA sequencing company based in San Jose, Santa Clara, CA. Genia was sold to Roche in June 2014. He is an active private equity investor. Previously, he was the Co-Founder and CEO of Brokat Technologies, an encryption banking software company. Brokat reached a several billion dollar market cap and went public in 1998 on the Frankfurt Stock Exchange and on NASDAQ in 2000. Mr. Roever was honored with the Ernst and Young Entrepreneur of the Year Award in Germany. He is an active private equity investor and currently serves as Chairman of WRS Materials, a roll-up of wafer reclaim companies. Mr. Roever also is a two time award holder of Technology Pioneer by the World Economic Forum. He earned degrees in both economics and law from the University of Tuebingen.

Speaker Profile

Ph.D., Co-Founder, Chief Technology Officer, Pacific Biosciences
Biography

Stephen Turner, PhD co-founded Pacific Biosciences in July 2000. Dr. Turner served as our President and Chief Executive Officer from the company’s inception until March 2004, when he assumed his current role as our Chief Technology Officer. He served as a member of our board of directors from inception until July 2010. Prior to founding the company Dr. Turner contributed to the establishment of the Nanobiotechnology Center at Cornell University in January 2000. Dr. Turner holds a PhD in Physics from Cornell University. He received B.S. degrees in Applied Mathematics, Electrical Engineering and Physics from the University of Wisconsin, Madison.

Speaker Profile

Ph.D., Partner, DeciBio Consulting
Biography

Dr. Stephane Budel is a partner at DeciBio Consulting with over 18 years of combined experience in life science business consulting, entrepreneurship and academic research. He specializes in helping companies commercialize novel and disruptive technologies in the life science research tools and diagnostic spaces. He has deep genomics expertise, especially as it relates to the impact of next generation sequencing. He has supported clients facing a broad range of challenging business issues, including product specification strategy and commercial due diligence. Dr. Budel earned his Ph.D. from Yale University for his research on the molecular mechanisms of schizophrenia.